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Abstract: The aim of this study was to perform a preformulation study of dexamethasone
(DXM)-loaded nanostructured lipid carriers (NLCs) for ocular use. Lipid screening was applied to
find the most suitable solid and liquid lipids and surfactant for the NLC formulation. The visual
observation was proved with XRD measurements for the establishment of the soluble state of DXM.
Thermoanalytical measurements indicated that the most relevant depression of the crystallinity index
could be ensured when using a 7:3 solid lipid:oil ratio. In order to optimize the NLC composition, a
23 full factorial experimental design was used. It was established that each independent factor (lipid,
DXM, and surfactant concentration) had a significant effect on the particle size while in the case of
entrapment efficiency, the DXM and surfactant concentrations were significant. Lower surfactant and
lipid concentrations could be beneficial because the stability and the entrapment efficacy of NLCs
were more favorable. The toxicity tests on human cornea cells indicated good ophthalmic tolerability
of NLCs. The in vitro drug release study predicted a higher concentration of the solute DXM on
the eye surface while the Raman mapping penetration study on the porcine cornea showed a high
concentration of nanocarriers in the hydrophylic stroma layer.
Keywords: dexamethasone; nanostructured lipid carrier; factorial design; zeta potential; particle size;
entrapment efficiency; human cornea cells toxicity; porcine cornea penetration; Raman mapping
1. Introduction
Vision significantly acts on quality of life while the effective treatment of ocular diseases presents
research & development specialists with a range of challenges. The anatomy, physiology, and
biochemistry of the eye create an effective barrier against foreign substances, therefore it is a challenging
task to achieve an optimal concentration of drug at the site of action for an appropriate time [1]. The
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eye has a small absorption surface and has many protection mechanisms, such as solution drainage,
lacrimation, blinking, tear turnover, conjunctival absorption, and the relative impermeability of the
corneal epithelial membrane. As a result, the most commonly used ophthalmic formulations, eye
drops, have a bioavailability of less than 5% [2], and frequent administration is required to provide a
therapeutic effect. However, frequent administration could decrease patient compliance and increase
the potential of side effects [3].
Topical non-invasive application of ophthalmic preparations is the most advantageous way of
drug administration, especially to the anterior segment of the eye. However, as we mentioned, the
bioavailability of therapeutic agents is very low in this way. In recent years, nanostructured lipid
carriers (NLCs) as lipid nanoparticles have been studied as potential ocular delivery systems. The use
of NLCs has many advantages in ophthalmic therapy. NLCs can be alternative delivery systems for
microemulsions or liposomes for ophthalmic administration because they can provide small particle
sizes (50–400 nm) while containing a lower emulsifier amount [4,5]. Compared with liposomes, higher
drug entrapment efficiency can be provided with the application of NLCs due to the decrease in lipid
crystallinity [6]. They may enhance corneal penetration and thereby improve bioavailability in a safe,
non-invasive, and patient-compatible way [7]. Furthermore, the possible mucoadhesive nature of
NLCs may improve their interaction with the cornea membrane, resulting in longer residence times,
increased bioavailability, and decreased local side effects. The possibility of scaling up to industrial
production is an incontrovertible advantage of these systems.
NLC preparations have been studied for the treatment of various disorders of the eye,
such as inflammation, infections, glaucoma, and disorders affecting the posterior segment of the
eye [7], where ophthalmic drugs, such as non-steroidal anti-inflammatory drugs (ibuprofen [8],
flurbiprofen [9], indomethacin [10]), steroidal anti-inflammatory drugs like triamcinolone acetonide [11],
and dexamethasone were incorporated in NLCs [12]. The literature data indicate that NLCs can also be used
to treat the anterior and posterior segments of the eye. For the treatment of the anterior segment of the eye,
Xiang Li et al. incorporated ibuprofen into NLCs, which resulted in apparent permeability coefficients 1.28
and 1.36 times higher than for the control composition while the AUC of the optimized NLC formulation
was 3.99 times higher in the aqueous humor than that of the conventional eye drops [8]. Enhanced
transcorneal permeation was achieved with flurbiprofen (FB) loaded NLCs by Gonzales-Mira et al., where
NLCs were prepared with stearic acid, castor oil, and Tween® 80, where a central composite rotatable
design 23 was used based on three independent variables (oil concentration, Tween® 80 concentration,
flurbiprofen concentration). This was a useful tool for optimizing FB-loaded NLC formulations. The
developed systems were physically and chemically stable and had high ocular tolerance [9].
The permeation of the therapeutic agents from the eye surface into the posterior segment is very
poor, so there is a need for alternatives to more effective invasive pathways, such as intravitreal and
subconjunctival injections. These invasive administrations have high risks of infections, bleeding, and
loss of vision [7]. For the posterior segment therapy, Balguri et al. formulated indomethacin-based
NLCs. NLC formulations showed increased drug load capacity, occlusive effect, and drug delivery
into the front and back segments of the eye tissues [10].
Corticosteroids are often used in the treatments of various ophthalmic inflammatory diseases,
for instance, after complicated eye surgery and corneal transplantation, and for severe uveitis. In
many cases, the therapy should be supplemented with systemic corticosteroids or by intraocular
or subcutaneous injections. Both frequent eye drops and systemic and/or intraocular supplement
therapies can lead to side effects and decreasing patient compliance [13]. Araújo et. al. encapsulated
triamcinolone acetonide (TA) into NLCs in order to increase its eye bioavailability. TA is a corticosteroid
drug, currently administered by intravitreal injection, for the treatment of a broad spectrum of
inflammatory, oedematous, and angiogenic eye diseases. Nanometric (~200 nm), unimodal and
negatively charged NLCs were developed to deliver the lipophilic TA through the cornea and the
non-cornea to the back segment of the eye. The results showed a quite stable particle size with a low
tendency of particle aggregation during storage [11].
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The aim of our study was to develop a dexamethasone (DXM)-loaded NLC composition for
ocular drug delivery in order to increase the poor water solubility and penetration of DXM, and
thus improve the bioavailability of this highly lipophilic drug. In our work, 0.05% and 0.1% DXM
concentrations were applied (these two concentrations can be found in the conventional eye drops
in the international market, e.g., MAXIDEX® eye drops, suspension with 0.1% DXM; and Maxidex®
ophthalmic ointment with 0.05% DXM concentration in phosphate salt). In the first part of our work,
lipid screening (solubility study, XRD, DSC measurements, formulation of NLCs) was applied for
the following purposes: (1) To find the most suitable solid and liquid lipids and surfactant that are
able to dissolve the required dose of DXM in the nano lipid particles; (2) to decrease the crystallinity
of the lipids in order to increase the drug loading capacity; and (3) to find the composition that can
form a nano system. In the second part of our work, a 23 full factorial design was applied for the final
optimization of the NLC compositions, where the zeta potential, particle size, and entrapment efficiency
were the optimization parameters used as indicators of the effective and stable nanoparticulate system.
The ophthalmic toxicity of the optimized formulations was analyzed by human cornea cells using
cell viability measurements. The effect of the optimized NLC formulation on the drug release and
penetration of DXM on the cornea was analyzed by carrying out in vitro drug diffusion and ex vivo
Raman mapping porcin cornea penetration studies.
2. Materials and Methods
2.1. Materials
DXM was purchased from Sigma-Aldrich (St. Louis, MO, USA). Compritol 888ATO (glycerol
dibehenate), Apifil (PEG-8 beeswax), and Labrasol (Caprylocaproyl Polyoxyl-8 glycerides) were kindly
supplied by Azelis Hungary Ltd. (Budapest, Hungary). Miglyol 812N (capric triglyceride) was
provided by Sasol GmbH (Witten, Germany). Kolliphor (or Cremophor) EL (Polyoxyl 35 hydrogenated
castor oil, HLB value: 12–14) and Cremophor RH60 (PEG-60 hydrogenated castor oil, HLB value:
15–17) were kindly supplied by BASF SE Chemtrade GmbH (Budapest, Hungary).
2.2. Lipid Screening
For the lipid screening, DXM in two concentrations (0.05 w/w% and 0.1 w/w% for the total NLC
system) was dissolved in the chosen lipid composition (lipid material or blends). The lipid compositions
were heated at 85 ◦C and DXM was added and mixed with a magnetic stirrer at about 100 rpm (Stuart
CB162 magnetic stirrer, Merck, Germany).
During the lipid screening, for the calculation of the DXM concentration in the lipids, 10 w/w%
and 15 w/w% total lipid contents of the final NLCs were taken as the basis. The investigated solid
lipids were Compritol 888 ATO, Apifil; the oils were Miglyol and Labrasol; and the surfactants were
Cremophor RH60 and Kolliphor EL.
2.2.1. Visual Observations of DXM Solubility
DXM solubility was investigated visually in the chosen lipid composition (solid lipids alone,
liquid lipids alone, and the mixtures of solid and liquid lipids with and without surfactant). The
DXM concentrations were 0.3% and 0.7% in the lipid mixture, which corresponded to a 0.05% and
0.10% DXM concentration, calculated with 15% lipid content in the final NLC formulations. The lipid
compositions were prepared on the basis of Section 2.2, and the melted lipid compositions (Sol 1–24)
were stirred for maximum 8 h at 85 ◦C. The visual observation of the insoluble DXM particles was
executed during these 8 h.
2.2.2. XRD Analysis of Lipid Mixtures
The solute state of DXM in the solidified lipid composition was analyzed with XRD. The lipid
mixtures (LMs) containing solid and liquid lipids in a 9:1 and 7:3 ratio (Table 1) were prepared on the
basis of Section 2.2.1, and the melts were cooled to room temperature and investigated after 24 h.
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The XRD measurements were performed with a Bruker D8 Advance diffractometer (Bruker AXS
GmbH, Karlsruhe, Germany). The Cu K λI radiation (λ = 1.5406 Å) was used. The samples were
scanned from 5◦ to 40◦ 2θ at 40 kV and 40 mA. The scanning speed was 0.1◦/s, and the step size was
0.010◦.
2.2.3. Investigation of Lipid Crystallinity with Differential Scanning Calorimetry (DSC) Measurements
The melting behavior and the crystallinity state (crystallinity index) of lipid mixtures and
DXM-containing lipid mixtures were examined with DSC (Mettler-Toledo 821e DSC instrument
(Mettler-ToledoGmbH, Greifensee, Switzerland). The sample preparation is described in Section 2.2.2.
Samples of 5 mg were weighed into aluminum pans, and sealed, and an empty aluminum pan was
used as a reference. The scanning was performed from 10 to 100 ◦C at the heating rate of 5 K/min. The
nitrogen flush (50 mL/min) was constant. The sample compositions are listed in Table 1.
Table 1. The composition of lipid mixtures (LMs) for XRD and DSC measurements in w/w%.
Sample Compritol888 ATO Apifil Labrasol
Miglyol
812N
Kolliphor
EL
Cremophor
RH60 DXM
LM-1 70.00 - - 30.00 - - -
LM-2 90.00 - - 10.00 - - -
LM-3 46.67 - - 20.00 - 33.33 -
LM-4 46.67 - - 20.00 33.33 - -
LM-5 60.00 - - 6.67 33.33 - -
LM-6 60.00 - - 6.67 - 33.33 -
LM-7 46.67 - - 20.00 - 33.33 0.33
LM-8 46.67 - - 20.00 33.33 - 0.33
LM-9 60.00 - - 6.67 33.33 - 0.33
LM-10 60.00 - - 6.67 - 33.33 0.33
LM-11 - 46.67 20.00 - - 33.33 0.33
LM-12 - 60.00 6.67 - - 33.33 0.33
LM-13 - 46.67 - 20.00 - 33.33 0.33
LM-14 - 60.00 - 6.67 - 33.33 0.33
From the results of the DSC measurements, the crystallinity index (CI%) of the lipid compositions
was calculated with Equation (1) [14]:
CI % =
∆Hbulk material × solid lipid ratio
∆Hsolid lipid
× 100. (1)
2.2.4. Investigation of NLC Formulations
The test NLC systems (T-NLCs) were prepared with the ultrasonication method. The solid lipid,
liquid lipid, and surfactant were melted with a heating magnetic stirrer at 85 ◦C. Then, DXM was
added to the melted lipid mixture and mixed in it. The pure water was heated at 85 ◦C and the two
phases were mixed and ultrasonicated (one cycle, 70% amplitude, 10 min) with a Hielscher UP200S
ultrasonic homogenizer (Hielscher Ultrasonics GmbH, Germany). The NLC systems were cooled in an
ice bath. The drug-free test NLC compositions (T-NLC) are in Table 2.
T-NLCs were analyzed by particle size and particle size distribution measurements using laser
diffraction, Mastersizer 2000 tool (Malvern Instruments, United Kingdom). The d(0.1), d(0.5) and d(0.9)
were assessed. The measuring medium was purified water with a refractive index (RI) of 1.33. The RI
of the samples was 1.36 and the imaginary RI was 0.01. The span value can be calculated with the
following Equation (2):
Span =
d(0.9) − d(0.1)
d(0.5)
. (2)
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Table 2. The composition of drug-free test NLCs (T-NLC) in w/w%.
Sample Compritol888 ATO Apifil
Miglyol
812N Labrasol
Kolliphor
EL
Cremophor
RH60
Purified
Water
T-NLC1 - 10.5 4.5 - 5.0 - 80.0
T-NLC2 - 10.5 4.5 - - 5.0 80.0
T-NLC3 10.5 - 4.5 - - 5.0 80.0
T-NLC4 10.5 - 4.5 - 5.0 - 80.0
T-NLC5 - 7.0 3.0 - 5.0 - 85.0
T-NLC6 - 7.0 3.0 - - 5.0 85.0
T-NLC7 7.0 - 3.0 - 5.0 - 85.0
T-NLC8 7.0 - 3.0 - - 5.0 85.0
T-NLC9 10.5 - - 4.5 - 5.0 80.0
T-NLC10 10.5 - - 4.5 5.0 - 80.0
T-NLC11 - 10.5 - 4.5 - 5.0 80.0
T-NLC12 - 10.5 - 4.5 5.0 - 80.0
T-NLC13 - 7.0 - 3.0 5.0 - 85.0
T-NLC14 - 7.0 - 3.0 - 5.0 85.0
T-NLC15 7.0 - - 3.0 5.0 - 85.0
T-NLC16 7.0 - - 3.0 - 5.0 85.0
2.3. Experimental Design
A 23 full factorial design was made, which is suitable for the investigation of the linear response
surface and for generating a first order polynomial model (Equation (3)). The model describes the
principal effects and interaction among the identified variables:
y = a0 + a1x1 + a2x2 + a3x3 + a12x1x2 + a23x2x3 + a13x1x3, (3)
where a0 is the intercept and a1,2,3 are the regression coefficient values. x1, x2, and x3 correspond to
factors A, B, and C, respectively.
The samples were prepared by the ultrasonication method to evaluate the effects of the three
DXM-NLC formulation factors. The factors were A (lipid concentration), B (DXM concentration), and
C (surfactant concentration). The optimization parameters (dependent factors) were the particle size
(hydrodynamic diameter, Zave), Zeta potential (ZP), polydispersity index (PI), and entrapment efficacy
(EE%). The chosen factors were examined at two levels (+1 and −1). Statistical data analysis was
performed using Statistica for Windows, version 10. The compositions of the factorial design can be
found in Table 3.
Table 3. The compositions of factorial design.
Sample Lipid Concentration(w/w%)
DXM Concentration
(w/w%)
Surfactant Concentration
(w/w%)
NLC1 10 0.05 2.5
NLC2 15 0.05 2.5
NLC3 10 0.10 2.5
NLC4 15 0.10 2.5
NLC5 10 0.05 5.0
NLC6 15 0.05 5.0
NLC7 10 0.10 5.0
NLC8 15 0.10 5.0
2.3.1. Particle Size and Zeta Potential of NLCs
The Zave, ZP, and PI of NLCs 1–8 were investigated by the Zetasizer Nano ZS instrument (Malvern
Instruments, Malvern, UK) with DTS 1070 folded capillary cell at 25 ◦C. The applied medium was
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purified water. The refractive index was 1.3553. Three parallel measurements were made, and 6-fold
dilution was used.
2.3.2. Entrapment Efficacy of NLCs
The EE% of NLCs was determined with an indirect method. The clear aqueous phase of the NLCs
was separated by centrifugation in Vivaspin 15R 5000 MWCO Hydrosart tubes (Sartorius, Stonehouse,
UK) with Hermle Z323K, (HERMLE Labortechnik GmbH, Wehingen, Germany). Centrifugation was
performed at 5000 rpm (9000 rcf), for 30 min at 4 ◦C.
The DXM content of the filtered solution was examined by high-performance liquid
chromatography (HPLC) (Shimadzu Nexera X2 UHPLC, Kyoto, Japan), which was equipped with a
C18 reverse-phase column (Phenomenex Kinetex EVO C18, Phenomenex, Torrance, CA, USA) with
dimensions of 1.7 µm, 100 Å, 100 × 2.1 mm. The mobile phase was water:acetonitrile 75:25 in isocratic
elution, and the detection was made at 240 nm. The injection volume was 5 µL and the flow rate was
0.5 mL/min. The column temperature was 40 ◦C. The time of analysis was 6 min and the retention time
for DXM was 3.5 min.
The following equation was used to calculate EE% (Equation (4)):
EE % =
Winitial drug −W f ree drug
Winitial drug
∗ 100. (4)
2.4. In Vitro Drug Release Study
Considering the results of the factorial experimental design, four NLC compositions were selected
for the diffusion study (Table 3; NLC1,3,5,7). To investigate the in vitro drug release, the dialysis bag
method was used [15]. Firstly, 200 µL of the samples (NLC1,3,5,7) were closed in a Spectra/Por® 4
dialysis membrane (Spectrum Laboratories, Inc., Rancho Dominguez, CA, USA), with Spectra/Por®
Closures (Spectrum Laboratories, Inc.). From each composition of NLCs, 3 replicates were used and
placed into 20 mL of phosphate-buffered saline (PBS) (PBS of pH = 7.4 was prepared by dissolving
8 g dm−3 NaCl, 0.2 g dm−3 KCl, 1.44 g dm−3 Na2HPO4.2H2O, and 0.12 g dm−3 KH2PO4 in distilled
water, the pH being adjusted with 0.1 M HCl). The sink condition was ensured during the experiments.
The systems were held at 35 ◦C to mimic in vivo conditions and stirred at 370 rpm with a magnetic
stirrer. During the diffusion study, seven sampling times were used (0.5, 1, 2, 3, 4, 5, and 6 h) by
removing 1 mL from the acceptor phase and replacing it with PBS to maintain sink conditions. As
a reference preparation, a DXM suspension (0.1 w/w%) was formulated (d(0.5) = 7.8 µm measured
by Mastersizer 2000). The diffused amounts of DXM were analyzed by HPLC (the HPLC method is
described in Section 2.3.2).
2.5. Cell Viability Measurements
For the cell culture experiments, all reagents were purchased from Sigma-Aldrich Kft., Hungary,
unless otherwise indicated. Human corneal epithelial cells (HCE-T; RCB 2280; RIKEN BRC, Tsukuba,
Japan) were immortalized by transfection with a recombinant SV40-adenovirus vector, established and
characterized by Araki-Sasaki [16]. The cells were grown in Dulbecco’s modified eagle’s medium/F-12
(Gibco, Life Technologies, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (Gibco, Life
Technologies, Carlsbad, CA, USA), 0.5% dimethyl sulfoxide (DMSO), 5 µg/mL recombinant human
insulin, and 10 ng/mL recombinant human epidermal growth factor (EGF) in a humidified incubator
with 5% CO2 at 37 ◦C. All plastic surfaces were coated with 0.05% rat tail collagen in sterile distilled
water before cell seeding in culture dishes. The culture medium was changed every second day. When
cells reached approximately 80% to 90% confluence in the dish, they were subcultured with 0.05%
trypsin/EDTA solution. For the MTT cytotoxicity assays, cells were cultured in 96-well plates (Corning
Life Sciences, Tewksbury, MA, USA) for 3 days.
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The metabolic activity and viability of the cells were used to measure by 3-(4,5-Dimethyltiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) dye conversion. The yellow MTT is enzymatically converted
by viable cells to purple formazan crystals. A decrease in formazan production reflects cellular damage.
Confluent HCE-T cultures were treated for 6 h. To prepare dexamethasone and Cremophor RH60
solutions, DMSO was used to dissolve the reagents. Treatment solutions were prepared in cell culture
medium, and the final concentrations were: 0.1 mg/mL for dexamethasone, and 2.5 and 5 mg/mL for
Cremophor RH60. The different formulations were diluted 10 and 100 times in cell culture medium.
After removing the treatment solutions, the cells were incubated with 0.5 mg/mL MTT solution for
1 h in a CO2 incubator. The amount of formazan produced by the cells was dissolved in DMSO and
determined by measuring the absorbance at the 570-nm wavelength with a microplate reader (Fluostar
Optima; BMG Labtechnologies, Ortenberg, Germany). Cell viability was calculated as the percentage
of dye conversion by non-treated cells. Triton X-100 (10 mg/mL) (TX-100) detergent was used as a
toxicity control. The investigated samples were NLC3, NLC7, Cremophor RH60, and DXM.
2.6. Porcine Corneal Penetration Study of NLCs
The porcine conjunctiva was obtained from a slaughterhouse and stored at −20 ◦C until the
measurement. The porcine cornea was placed onto a sterile cotton wool bed wetted with physiological
saline solution and the cornea was surrounded with a Teflon ring in order to avoid the flow of the eye
drop toward the conjunctiva. The cornea was instilled with 250 µL of NLC7 every 30 min, and the
formulation was removed just before the next instillation. The length of the treatment was six hours.
The system was thermostated at 35 ◦C. The treated cornea was frozen and sectioned (20 µm thick
cross-sections) onto aluminum-coated slides using a Leica CM1950 cryostat (Leica Biosystems GmbH,
Wetzlar, Germany). As a reference, an untreated porcine corneal section was used. Raman microscopy
measurements were performed with the Thermo Scientific DXR Raman microscope (Thermo Fisher
Scientifc, Waltham, MA, USA). A laser light of a 780-nm wavelength was used, and its maximum power
was 24 mW. The microscopic lenses used for measurements were magnified 50× and the aperture was
25 mm. The examined chemical mapping area was 150 × 1200 µm; the step size was vertically and
horizontally 50 µm. A total of 72 spectra were recorded, 16 images were collected for each spectrum,
and the exposure time was 5 s. The instrument operation and the evaluation of the measurements
were carried out by OMNIC for Dispersive Raman 8.2 software package (Thermo Fisher Scientifc).
The characteristic peaks of the DXM spectrum coincided with the characteristic peaks of the corneal
tissue, however, the profiled map showed a detectable signal of NLC7. For this reason, profiling of the
Raman map was performed on the spectrum of the full preparation during the evaluation.
2.7. Statistical Analysis
The drug release results were statistically analyzed with GraphPad Prism version 5 software.
Two-way ANOVA analysis was applied with Bonferroni post-tests. For the MTT assay, the values were
compared using ANOVA followed by Dunett’s test. The values are expressed as means ± standard
deviation (SD). A level of p ≤ 0.05 was taken as significant, p ≤ 0.01 as very significant, and p ≤ 0.001 as
highly significant.
3. Results and Discussion
3.1. Lipid Screening
NLCs contain solid lipid, liquid lipid, and surfactant in an aqueous medium. The EE% of
lipid nanoparticles can be improved by reducing the crystallinity of solid lipids. The liquid lipid
decreases the crystallinity index of solid lipids in blends, and thus the crystallinity of lipid nanoparticles.
The application of surfactants can also decrease the crystallinity index of lipid particles and help to form
a nano emulsion system during the formulation, and their presence at the water–lipid interface can
ensure the stability of nanoparticles. It is important to note that the surfactant can cause irritation and
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toxicity, especially on the eye. Therefore, in the case of NLC systems, a lower surfactant concentration
may be sufficient. In our work, the selection criteria of the components were a low irritation potential,
eye tolerability, and suitability for NLC formulation based on the literature background. Tayel et al.
(2013) examined a Cremophor EL-containing formulation on in vivo rabbit eyes and it provoked no
histopathological alteration in the investigated tissues, including the cornea, iris, retina, and sclera [17].
The lipid screening focused on three potential critical factors that may have an effect on the
performance of NLCs. The first was to find lipid compositions that are able to solve the applied dose
of DXM. In the first part of the solubility study, a cost-effective method of visual observation was
used to detect insoluble DXM crystals in the different combinations of lipid melts. In the second part
of this study, the solubility of DXM in the solidified lipids was analyzed with XRD measurements.
The second critical factor is the crystallinity of the applied lipids because their crystallinity index
(CI%) may have an effect on the drug loading capacity of NLCs. This factor was investigated with
DSC measurements. The third critical factor is the ability of the lipid–surfactant blends to form an
NLC formulation, therefore blank (drug-free) test NLCs (T-NLCs) were formulated and analyzed by
laser diffraction.
3.1.1. Visual Observations of DXM Solubility
In this part of the solubility study, a fast screening method of the visual observation of different
combinations of lipid melts, including solid lipids, liquid lipids alone, and their mixtures with and
without surfactant (Table 4), was applied. When insoluble particles were observed in the thin layer of
the melted lipid, it was considered as not solved.
Table 4. The composition of lipid matrices in the solubility study.
Sample Compritol888 ATO Apifil
Miglyol
812N Labrasol
Kolliphor
EL
Cremophor
RH60 DXM Solubility
Sol-1 89.7 0.3 -
Sol-2 89.3 0.7 -
Sol-3 89.7 0.3 -
Sol-4 89.3 0.7 -
Sol-5 89.7 0.3 -
Sol-6 89.3 0.7 -
Sol-7 89.7 0.3 +
Sol-8 89.3 0.7 +
Sol-9 66.3 33.3 0.3 +
Sol-10 66.0 33.3 0.7 -
Sol-11 66.3 33.3 0.3 +
Sol-12 66.0 33.3 0.7 -
Sol-13 66.3 33.3 0.3 +
Sol-14 66.0 33.3 0.7 +
Sol-15 66.3 33.3 0.3 +
Sol-16 66.0 33.3 0.7 +
Sol-17 46.7 20.0 33.3 0.7 +
Sol-18 46.7 20.0 33.3 0.7 +
Sol-19 46.7 20.0 33.3 0.7 +
Sol-20 46.7 20.0 33.3 0.7 +
Sol-21 46.7 20.0 33.3 0.7 -
Sol-22 46.7 20.0 33.3 0.7 -
Sol-23 46.7 20.0 33.3 0.7 +
Sol-24 46.7 20.0 33.3 0.7 +
The active pharmaceutical ingredient (API) could not be dissolved in the chosen lipids with the
exception Labrasol, which was able to dissolve DXM in both concentrations. In the Compritol and
Kolliphor RH60 mixtures, the API in a low concentration (0.3 w/w%) could be dissolved completely
while the dissolution of a high concentration (0.7 w/w%) of DXM was partial. The same tendency was
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seen in the case of the Kolliphor EL and Compritol 888 ATO mixture. In the Apifil and surfactant
mixtures, the API was dissolved in both concentrations. In this solubility study, there was no difference
between the two solid lipids (Compritol 888 ATO, Apifil). Compared to Miglyol, Labrasol was much
more effective at dissolving API. In the case of solid lipid (Compritol 888 ATO), oils (Miglyol, Labrasol),
and surfactant (Cremophor RH60, Kolliphor EL)-containing mixtures, DXM was dissolved in almost all
cases, except for Sol-21 and Sol-22, where the mixtures were made with Apifil, Miglyol, and Cremophor
RH60(Sol-21)/Kolliphor EL(Sol-22).
3.1.2. XRD Analysis of Lipid Mixtures
The visual observation revealed that the lipid mixtures containing solid, liquid lipids, and
surfactant were able to solve the required DXM amounts. XRD is a technique used to investigate the
solid state of a drug, giving information about its amorphous or crystalline nature. The disappearance
of the crystalline peaks mainly indicates the amorphous form of the drug within the lipid matrix and/or
its molecularly dispersion in the lipid. In this section, 7:3 and 9:1 ratios of the solid and liquid lipids
were evaluated.
During the XRD measurements, the presence of the diffraction peaks of crystalline DXM was
investigated. The X-ray diffraction pattern of dexamethasone showed major peaks at 2θ = 6.1, 9.1, 10.9,
12.86, 14.66, 15.4, and 17.02 in our measurements, similar to the investigation by Ali et al. (2013) [18].
The fact that the characteristic peaks of crystalline DXM are not detectable can prove its amorphous
form and/or molecular dispersion in all the lipid matrices and it can be concluded that the ratio of the
solid and liquid lipids did not influence it (Figure 1).
On the other hand, the characteristic peaks of the solid lipids (the characteristics peaks of Apifil
are 2θ = 21.51, 39.32, 36.06, 5.67 and the main peaks of Compritol 888 ATO are 2θ = 4.27, 21.25, 22.97)
can be found in the lipid mixtures, indicating the presence of some crystalline solid lipid in all cases.
The amount of crystalline solid lipid is detailed with the DSC measurements in Section 3.1.3.
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3.1.3. Investigation of Lipid Crystallinity with DSC Measurements
Lipid crystallization plays a very important role in the performance of NLC carriers because it has
a great influence on the drug loading capacity of lipid particles and the drug release from them.
It must be considered that the application of liquid lipids/oily components can decrease the melting
point of the lipid nanoparticle, which can result in easy diffusion of the API from the nanocarriers.
From this point of view, the melting behavior of the lipid mixture can be an important factor because it
can predict the permanence of the amount of the incorporated drug in the nanocarriers during storage
and can have an influence on the evaluation of the drug effect.
As it was mentioned, a strategy to decrease crystallinity is the application of liquid lipids. In our
work, two oil and solid lipid ratios (7:3 and 9:1) were evaluated. On the other hand, emulsifiers can
also have an effect on the crystallinity, so two emulsifier types (Cremophor RH60 and Kolliphor EL) in
the same concentration were also investigated in this section.
Based on the results, it can be seen that Cremophor RH60 decreased the melting point of the lipid
mixture in the case of the 7:3 solid lipid:oil ratio (samples LM-3 and LM-7). In the case of Kolliphor EL
(LM-4,5) and the 9:1 solid lipid:oil ratio, this decrease in the melting point was not experienced.
The two emulsifiers (Cremophor RH60 and Kolliphor EL) reduced the crystallinity index, but
there was no remarkable difference between them (Table 5). The higher liquid lipid concentration
resulted in the most relevant CI% depression. The presence of the API (samples LM 7–10) can also
change the CI%, but just in the case of the 7:3 solid lipid:oil ratio. In this latter case, the slight increase
in CI% (LM-7: 23.26 vs. LM-3: 20.95, and LM-8: 23.11 vs. LM-4: 18.33) could be observed.
Table 5. The crystallinity index (%) and melting point peaks (◦C) of the lipid mixtures in Table 2.
Sample Peak (◦C) Crystallinity Index (%)
LM-1 70.48 47.09
LM-2 72.22 82.90
LM-3 67.68 20.95
LM-4 70.74 18.33
LM-5 70.28 36.84
LM-6 70.42 36.26
LM-7 67.04 23.26
LM-8 68.30 23.11
LM-9 69.94 37.92
LM-10 69.44 34.02
Thanks to the favorable CI% depression effect of the 7:3 solid lipid:oil ratio (with minimal melting
point depression), this ratio was applied for further optimization.
3.1.4. Investigation of NLC Formulations
In order to clarify the ability of the chosen lipid mixtures to form a nanosystem, drug-free test
NLCs (T-NLCs) were made. To characterize the NLC systems, the following factors were measured
using the laser diffraction method: d(0.1), d(0.5), d(0.9), and span values.
On the basis of Equation (2), the lower span value (at about 1 or less) indicates a more
monodispersed distribution, thus better stability for NLC systems. The span value was high for
T-NLCs 1, 5, 6, and 11. The T-NLCs made with Apifil (T-NLCs 1, 2, 5, 6, and 11) had higher span
values than Compritol 888 ATO-containing NLCs (Table 6). The mixtures containing Labrasol as liquid
lipid did not form NLC systems (T-NLCs 10–16); the only exception was T-NLC 11, where nanosized
particles could be detected but the span value was very high (2.776) (Table 6). As a consequence,
Labrasol as an oil component was excluded from further measurements.
The lowest span value was found for T-NLC 3, which was made with Compritol 888 ATO, Miglyol,
and Cremophor RH60. So, components of T-NLC 3, such as Compritol 888 ATO, Miglyol 812N, and
Cremophor RH60, were chosen for further measurements and formulation optimization.
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Table 6. The d(0.1), d(0.5), d(0.9), and span value of test NLCs.
Sample d(0.1) d(0.5) d(0.9) Span Value
T-NLC1 1.585 6.095 24.088 3.692
T-NLC2 0.066 0.130 0.308 1.859
T-NLC3 0.077 0.115 0.172 0.830
T-NLC4 0.071 0.121 0.210 1.140
T-NLC5 2.426 7.959 26.088 2.973
T-NLC6 0.066 0.132 0.362 2.241
T-NLC7 0.067 0.136 0.299 1.707
T-NLC8 0.075 0.120 0.192 0.975
T-NLC9 - - - -
T-NLC10 - - - -
T-NLC11 0.112 0.388 1.188 2.776
T-NLC12 - - - -
T-NLC13 - - - -
T-NLC14 - - - -
T-NLC15 - - - -
T-NLC16 - - - -
- not measurable.
3.2. Optimization of DXM-Loaded NLCs with Factorial Experimental Design
During the lipid screening, we could conclude that the optimal components for NLC formulation
are Compritol 888 ATO, Miglyol 812N, and Cremophor RH60 with a 7:3 solid lipid:liquid lipid ratio. To
evaluate the effect of the component concentration and find the optimal ratio, a factorial experimental
design was used. With the application of a 23 full factorial design, over the optimal ratio, information
about the interactions of factors can also be provided. Three formulation parameters of DXM-NLC
were chosen as independent factors (the concentration of the emulsifier, the drug, and the total lipid).
As for the optimization parameters (dependent factors), the particle size (Zave), zeta potential (ZP),
polydispersity index (PDI), and entrapment efficacy (EE%) of the NLC systems were chosen.
As it was mentioned above, the emulsifier is essential for the formulation of NLC systems, but it
can be the main irritating and toxic component of the formulations. For this reason, an effort should
be made to minimize the amount of surfactant. In the factorial design, the two levels of emulsifier
concentration were 5% and 2.5%. As the high lipid concentration can make it possible to solve more
API, 10% and 15% total lipid contents were evaluated with 0.05% and 0.1% total DXM concentrations
during our experiments.
EE% provides information about the amount of DXM, which can be incorporated into the lipid
matrix of the NLC.
ZP is a key indicator of the stability of colloid dispersions. The magnitude of ZP indicates the
degree of electrostatic repulsion between adjacent, similarly charged particles in the dispersion. For
molecules and particles that are small enough, the high absolute value of ZP provides stability, and
these dispersions have moderate aggregation. If the absolute value of ZP is low, the attractive forces
may exceed this barrier and the dispersion may break and flocculate. Thus, colloids with a high
ZP (negative or positive) are electrically stabilized while colloids with low ZP tend to coagulate or
flocculate [19,20]. In the case of an electrostatic and steric stabilized system, about ZP ± 20 mV is
advised [7].
PDI is used to estimate the average uniformity of a dispersed solution, and larger PDI values
correspond to a larger size distribution in the dispersed sample. PDI can also indicate nanoparticle
aggregation and the stability of the dispersed system. A sample is considered monodispersed when
the PDI value is less than 0.1. The low PDI (0.1–0.25) shows a narrow size distribution [7] while PDI
over 0.5 indicates a wide size distribution, resulting in more polydispersity [21,22].
As indicators of the stability of NLCs, the optimization parameters were measured after preparation
(after 24 h), and also after 1 month (except for EE%) (Table 7). On the basis of the results, the particle
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size of the NLC systems was less than 300 nm and the PDIs were less than 0.2, which means a narrow
size distribution in all cases. The smallest particles and the narrowest size distributions were detected
in the case of NLCs 5 and 7, where the total lipid concentration was low (10 w/w%) and the surfactant
concentration was high (5 w/w%). The ZP values changed between 8 and 15, which corresponds to
the literature data, where the ZP of NLC prepared with the Cremophor-type emulsifier was about
−12 mV [23]. These values, the low particle size, and the narrow size distribution can help to retain
the stability of the nano systems. The EE% of the nano lipids was very high, over 87%, indicating the
good drug loading capacity of the nano lipid carriers. EE% was better in the NLCs containing lower
surfactant concentrations (NLCs 1–4), which may be explained by the appearance of the redundant
surfactant in the aqueous phase, which can dissolve DXM in the aqueous phase in a higher amount.
When the samples were measured after 1 month, in two compositions (NLCs 4 and 6), the
aggregation of the nano lipid particles resulted in the formation of a lipid cake on the top of the
container, therefore none of the tested parameters could be measured in these cases. In the case of the
homogenous samples, it could be observed that the PDI values remained within the narrow size. The
absolute ZP values (if it was applicable) increased with storage time (after 1 month), which means the
aqueous–lipid interface changed and became more stable after 1 month.
Table 7. The Zave, PDI, zeta potential, and EE% of NLCs 1–8.
After 1 Day After 1 Month
Sample Zave (d.nm) PDI ZP (mV) EE% Zave (d.nm) PDI ZP (mV)
NLC1 196.47 ± 3.91 0.19 ± 0.01 −14.00 ± 0.1 93.81 194.40 ± 0.66 0.20 ± 0.01 −28.87 ± 9.90
NLC2 261.73 ± 2.44 0.18 ± 0.01 −14.43 ± 0.80 94.68 265.17 ± 1.70 0.18 ± 0.02 −21.30 ± 0.56
NLC3 182.97 ± 1.85 0.14 ± 0.01 −10.97 ± 0.25 92.66 183.20 ± 0.82 0.17 ± 0.01 −18.70 ± 0.46
NLC4 256.83 ± 0.78 0.19 ± 0.01 −13.67 ± 0.49 93.05 n.m n.m n.m
NLC5 94.60 ± 0.66 0.12 ± 0.00 −9.71 ± 0.15 91.89 102.60 ± 0.61 0.23 ± 0.01 −18.83 ± 2.83
NLC6 143.90 ± 1.47 0.16 ± 0.02 −10.53 ± 0.75 91.97 n.m n.m n.m
NLC7 92.18 ± 0.49 0.12 ± 0.02 −7.62 ± 0.26 88.31 91.38 ± 0.25 0.15 ± 0.02 −17.13 ± 0.35
NLC8 150.33 ± 2.31 0.19 ± 0.00 −8.30 ± 0.15 87.24 143.17 ± 0.57 0.19 ± 0.01 −16.40 ± 2.78
n.m: not measurable.
A mathematical model was used to analyze the single and combined effect of the factors. The
coefficients in the equations describe the size and direction (negative: Inversely proportional; or positive:
Directly proportional) of the relationship between a term in the model and the response variable [24].
The mathematical model is shown in the following equations (Equations (5)–(8)) of the response
surfaces:
EE% = 91.7 + 0.03 A − 1.39 B − 1.85 C − 0.20 AB − 0.28 AC − 0.69 BC, (5)
Zave (d.nm) = 171.38 + 30.82 A − 1.80 B − 52.12 C + 2.18 AB − 3.96 AC + 2.80 BC, (6)
PDI = 0.16 + 0.02 A + 0.00 B − 0.01 C + 0.01 AB + 0.01 AC + 0.01 BC, (7)
ZP (mV) = −11.15 − 0.58 A + 1.02 B + 2.11 C − 0.27 AB + 0.20 AC + 0.07 BC, (8)
where factor A is the lipid concentration, B is the DXM concentration, and C is the surfactant
concentration.
The results suggest that EE% depends on DXM and the surfactant concentration (inversely
proportional) as well (Figure 2d). The combined effect of factors is also inversely related to EE%. On the
basis of the coefficient value, the changes of entrapment efficiency are significant (higher coefficient
values) with the DXM concentration and surfactant concentration while the combined effect of the
factors is not remarkable (lower coefficient values). The mathematical model demonstrated that the
lipid content does not influence EE% (very low coefficient value), so in this total lipid concentration
range (10–15%), the drug loading capacity of NLCs cannot improve by increasing this concentration.
Zave is also affected by lipid (directly proportional), DXM, and surfactant concentration (inversely
proportional) (Figure 2a–c), but the amount of surfactant showed the most remarkable impact. The
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combined effect of factors is less expressed as it was observed in the case of EE%, too. The increase
of the surfactant amount can be beneficial for particle size reduction, but as we could conclude from
Equation (4), it can deteriorate the drug loading capacity (lower EE% values).
Concerning PDI, very low coefficient values were calculated. In this case, the preparation
technique and/or type of composition may have a more relevant influence on it, but these parameters
were constant in our current experiments.
ZP is influenced by DXM, surfactant (directly related), and lipid concentration (inversely related).
As it was concluded in the case of EE% and Zave, the combined effect of factors does not have a
considerable effect on it. The most remarkable effect can be observed in the case of the surfactant,
which means the increase in the surfactant concentration can improve the stability of NLCs (higher
absolute ZP value), but higher values were found to reduce EE%.
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3.3. In Vitro Drug Release Study
In order to compare our optimized NLCs with the conventional suspension form, in vitro drug
release studies were performed. On the basis of the results of our factorial experimental design, the
four most relevant compositions were chosen to be compared with 0.1% DXM suspension. Two of the
chosen compositions (NLC3 and 7) contained the same concentration of DXM (0.10%) as in the case of
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the suspension while two of them (NLC1 and 5) contained half the amount (0.05%) of that. The drug
release profile of the formulations is shown in Table 8.
Table 8. Summary of the drug release study: the rate constant (K) and the correlation coefficient (R2) of
the Higuchi model, the amount of the released DXM at 6 h of the release study; and the results of the
statistical analysis, where the NLCs were compared with the DXM suspension.
Formulation
Higuchi Model
Released DXM at 6 h (µg) Results of the Statistical Analysis
K R2
DXM Suspension 3.69 0.9836 68.5 ± 4.5 reference system
NLC1 3.65 0.9967 56.7 ± 4.8 highly significant (p ≤ 0.001) from 0.5 h
NLC3 6.73 0.9940 104.2 ± 5.2 highly significant (p ≤ 0.001) from 3 h
NLC5 4.68 0.9971 76.2 ± 0.2 significant (p ≤ 0.05) at 6 h
NLC7 9.26 0.9968 140.5 ± 0.2 highly significant (p ≤ 0.001) from 1 h
The mathematical modelling of the in vitro release data showed the DXM release from NLCs and
suspension followed Higuchi release kinetics (R2 is higher than 0.99 for NLCs, and higher than 0.98 for
suspension). This type of kinetics indicates a diffusion-controlled release from the systems (Table 8).
It could be clearly seen the NLCs containing 0.10% DXM showed a remarkable drug release, at 6 h. The
amounts of the released drug from NLC7, NLC3, and the DXM suspension were 140, 104, and 68 µg,
respectively (Figure 3). These results can predict a 100% increase in drug release using NLC7. When
we consider the NLCs containing 0.05% DXM, the NLC-1 composition displayed a lower amount of
the released drug at each time point while the NLC5 composition was similar to the suspension form
(no significant differences during the drug release, except at 6 h, where a significantly higher drug
amount was detected in the case of NLC5). This finding can also confirm that the NLC composition
can increase the amount of the released drug.
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3.4. Cell Viability Assay
In order to analyze the possible toxicity of the formulated NLCs, a human cornea cell viability
study was applied, where the most relevant compositions (NLC3 and 7) based on the drug release
study, the emulsifier (Cremophor RH60), and DXM were investigated [4].
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During the colorimetric assay, NLC3 and NLC7 formulations at 10× dilution slightly decreased
the viability of the HCE-T cells by 10% and 19%, respectively, after the 6-h treatment. The 100×
dilutions did not cause any significant alteration in the cell index, indicating no cell damage (Figure 4).
Cremophor RH60 did not reduce the cell viability of the epithelial cells at either the 2.5 or 5 mg/mL
concentration for 6 h (Figure 4). These results are in accordance with our previous studies, where
concentrations of Cremophor RH40 less than 10 mg/mL were non-toxic for different cultured epithelial
cells [25,26].
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3.5. Porcine Corneal Penetration Study of NLCs
Topically applied ophthalmic formulations are faced with a number of elimination mechanisms
and barriers that reduce the bioavailability of the active ingredients. After instillation, tear production
slightly increases in order to wash away the foreign material from the surface of the eye. Following this,
through the nasolacrimal sac, the material washed out can enter into the systemic circulation, increasing
the risk of potential side effects. In addition, a part of the active agent can also be eliminated via the
highly vascularized conjunctiva, further reducing the possibility of its penetration into the deeper ocular
tissue layers [27]. The main absorption way of the topically applied drugs is through the cornea, which
has a remarkable barrier function. The cornea consists of three main layers: The epithelium (next to the
conjunctiva), the stroma (the middle layer), and the endothelium (the inner layer). The epithelium and
the endothelium are lipid-rich layers that limit the absorption of hydrophilic drugs while the stroma as
an aqueous layer limits the permeation of lipophilic substances. In addition, both the conjunctiva and
the corneal epithelium have tight junctions that limit the absorption of substances (regardless of their
physicochemical properties) by paracellular permeation, further reducing the bioavailability [27,28].
DXM as a lipophilic drug is considered to be able to penetrate through the epithelial layer, but
the stromal layer of the cornea is a significant barrier for this molecule. When DXM is present in a
suspension form, a part of it is removed from the ocular surface due to the elimination mechanisms
following administration. A part of the suspended lipophilic drug might be soluble in the lipophilic
layer of the tear film and can be present in higher concentrations than in the aqueous layer of the tear
film. It may penetrate into the lipophilic epithelium but is supposed to poorly penetrate across the
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hydrophilic stromal layer. However, when NLC is used, it is probable that the better distribution and
lower mechanical irritation (less foreign material sensation) of the nano-sized material can result in
decreased elimination. The active ingredient will also be present in the lipophilic layer of the tear
film as well as in the lipophilic epithelial layer, like in the case of the conventional suspension form.
However, the nanocarrier can also pass through the hydrophilic stromal layer and can be distributed
in it due to its small size and emulsifier content.
In order to follow the penetration of nanocarriers through the cornea, in our study, semi-
quantitative Raman mapping was applied, where porcine cornea was treated with NLC formulation,
and the penetration depth was analyzed.
Based on the results of the in vitro drug release study, NLC7 was chosen for the penetration study.
NLC7-treated porcine cornea specimen was compared with non-treated cornea specimen using
Raman correlation mapping. The spectrum of NLC7, containing DXM as well, was used for the
cornea distribution correlation maps. Figure 5 shows a high Raman intensity on the top of the cornea
specimens in both cases (non-treated, treated), which can correspond to the high lipid content of the
epithelial layer and the surface of the tear film. In contrast, the NLC7-treated cornea has a higher
Raman intensity for the lipid components in the 200–400 µm depth of the cornea, the depth of which
corresponds to the stroma layer. This observation means the nanocarriers entered and enriched in
the hydrophilic part of the cornea, which is considered as a main limiting barrier for hydrophobic
materials. Based on these results, the penetration of DXM through the cornea might be achieved by
using nano lipid carriers.
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4. Conclusions
Successful formulation of non-toxic potential ophthalmic NLC systems was carried out with
a narrow size distribution, high DXM entrapment efficacy, and improved penetration. The chosen
components were Compritol 888 ATO, Miglyol 812N, and Cremophor RH60. We propose the use of
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low levels of surfactant concentration and lipid concentration (e.g., 2.5% for surfactant and 10% for
total lipid) because then the critical stability parameters (Zave, ZP, PDI) and drug loading capacity
(EE%) are suitable while the emulsifier concentration can remain at low levels.
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